Voyageur Brewing Company Serving Great Beer for a Great Cause Brewery participating in 3rd Annual Ales for ALS Fundraiser

Grand Marais, MN June 15^th, 2015 Voyageur Brewing Company is one of fewer than 80 breweries in the nation to participate in Ales for ALS. This special opportunity allows the brewery to donate $1 per pint of Ale sold to the ALS Therapy Development Institute.

 

Each participant was given a special blend of experimental hops donated by B.T. Loftus Ranches and Hopunion. Using those hops Voyageur brewer Jason Baumgarth created a Summer Ale with notes of citrus, tropical fruit and pine.

 

One of the owners of Voyageur Brewing Company had an Aunt pass away from ALS. Cara Sporn said, “We’re proud to be participating in this fundraiser. I lost my Aunt Ruth to this debilitating disease in 2011 and whatever we can do to help find a cure for ALS is an honor.”

 

Participating brewers release their limited edition beer sometime during June or July. Voyageur is releasing theirs in their taproom on Tuesday, June 23rd. The special blend will only be available for a short time due to the limited amount of hops provided.

 

Voyageur Brewing Company is a production brewery in Grand Marais, Minnesota that opened in February of 2015. Their taproom provides patrons with an amazing view of Lake Superior from inside or outside on their rooftop patio.

 

 

More information:

 

Ales for ALS™ is a unique craft brewery-based fundraising initiative created to accelerate drug development for people living with ALS also known as Lou Gehrig’s disease. For more information about Ales for ALS, visit http://ift.tt/1lvsVU6.
The mission of the ALS Therapy Development(ALS TDI) is to discover and develop effective treatments for ALS patients today as soon as possible. ALS TDI is the world’s largest independent ALS/MND drug development-focused nonprofit organization. In addition to more than 30 internal therapeutic aimed programs, the world’s first nonprofit biotech partners with dozens of pharmaceutical and biotechnology companies worldwide in order to advance potential treatments into the clinic. Its lead ALS therapeutic candidate, Novartis’ (Switzerland) Gilenya (TDI-132), is in Phase 2A clinical trial for ALS. For more information on its drug development programs, visit http://www.als.net.

 

Contact:

Sue Prom

218-388-2224

sue@voyagerbrewing.com

The post Voyageur Brewing Company Serving Great Beer for a Great Cause Brewery participating in 3rd Annual Ales for ALS Fundraiser appeared first on CraftBeer.com.

from CraftBeer.com http://ift.tt/1TqwtLx
via IFTTT